Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638680 | 0.98 | KCNH2 (0.45) | KCNH2MAPTBCHEDRD2OPRM1 | |
| SCHEMBL6634540 | 0.93 | MAPT (0.50) | KCNH2MAPTBCHEDRD2OPRM1 | |
| SCHEMBL6637302 | 0.87 | KCNH2 (0.44) | KCNH2MAPTBCHEOPRM1DRD3 | |
| SCHEMBL6638418 | 0.86 | SIGMAR1 (0.49) | KCNH2 | |
| SCHEMBL6667357 | 0.80 | HRH3 (0.43) | KCNH2BCHEDRD2OPRM1DRD3 | |
| SCHEMBL6235591 | 0.79 | HRH3 (0.47) | KCNH2BCHEOPRM1DRD3 | |
| SCHEMBL9005882 | 0.79 | KCNH2 (0.66) | KCNH2MAPTBCHEDRD2OPRM1 | |
| SCHEMBL1262236 | 0.79 | KCNH2 (0.66) | KCNH2MAPTBCHEDRD2OPRM1 | |
| SCHEMBL3453399 | 0.79 | KCNH2 (0.66) | KCNH2MAPTBCHEDRD2OPRM1 | |
| SCHEMBL7606887 | 0.79 | KCNH2 (0.66) | KCNH2MAPTBCHEDRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165557-B1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS | NEUROGEN CORP (US) | 2004-09-29 | — | — | EP | claimed |
| US-6627624-B1 | Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, | NEUROGEN CORPORATION | 2003-09-30 | — | — | US | claimed |
| EP-1165557-B1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS | NEUROGEN CORP (US) | 2004-09-29 | — | — | EP | disclosed |